China SXT Pharmaceuticals (SXTC) Non-Current Debt (2019 - 2026)

China SXT Pharmaceuticals (SXTC) has reported Non-Current Debt for 8 consecutive years, with $644390.0 the latest figure, recorded in Q1 2026.

• Quarterly Non-Current Debt rose 569.4% year-over-year to $644390.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $644390.0 (up 569.4% YoY) and the FY2026 annual result came in at $644390.0, up 569.4% from the prior year.
• Non-Current Debt advanced to $644390.0 in Q1 2026 per SXTC's latest filing, from $73102.0 in the prior quarter.
• Over the last five years, Non-Current Debt for SXTC reached as high as $1.1 million in Q1 2022 and fell as low as $73102.0 in Q3 2025.
• A 5-year average of $299140.5 and a median of $116236.5 in 2024 frame the typical range for Non-Current Debt.
• Annual changes were most pronounced in 2022 — Non-Current Debt plunged 90.76% — and 2026, when it surged 569.4%.
• Year by year, Non-Current Debt stood at $1.1 million in 2022, then sank by 90.51% to $106575.0 in 2023, then gained by 8.23% to $115344.0 in 2024, then plunged by 36.62% to $73102.0 in 2025, then surged by 781.49% to $644390.0 in 2026.
• According to Business Quant data, Non-Current Debt over the past three periods registered $644390.0, $73102.0, and $96264.0 for Q1 2026, Q3 2025, and Q1 2025 respectively.